{"id":14639,"date":"2026-11-16T08:00:58","date_gmt":"2026-11-16T07:00:58","guid":{"rendered":"https:\/\/www.cilcare.com\/?p=14639"},"modified":"2026-11-12T14:48:14","modified_gmt":"2026-11-12T13:48:14","slug":"cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi","status":"publish","type":"post","link":"https:\/\/www.cilcare.com\/jp\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/","title":{"rendered":"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"14639\" class=\"elementor elementor-14639\" data-elementor-settings=\"{&quot;ha_cmc_init_switcher&quot;:&quot;no&quot;}\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4734c701 e-flex e-con-boxed e-con e-parent\" data-id=\"4734c701\" data-element_type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9d70437 elementor-widget elementor-widget-text-editor\" data-id=\"9d70437\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><strong><em>CIL005 and CIL006 extend Cilcare\u2019s pipeline to new mechanisms of hearing loss and new patient populations<\/em><\/strong><\/h3><p><strong>Montpellier, France, November 16, 2026 \u2013 <\/strong><strong>Cilcare, a biotechnology company pioneering auditory science, today announced exclusive licensing agreements with <a href=\"https:\/\/www.sanofi.com\/en\">Sanofi<\/a> for two therapeutic assets, CIL005 and CIL006. The programs expand Cilcare\u2019s proprietary pipeline beyond cochlear synaptopathy, the focus of its lead candidate CIL001.<\/strong><\/p><h1><strong>Two programs targeting complementary mechanisms<\/strong><\/h1><p>As in any other organ, the inner ear relies on many cell types, each of which can be damaged through distinct biological mechanisms that define different disorders and patient populations. CIL005 and CIL006 expand Cilcare\u2019s pipeline into two complementary areas of hearing biology. \u00a0<strong>CIL005 targets cochlear inflammation<\/strong>, a key driver of hearing damage caused by noise, ototoxic treatments, infection or autoimmune conditions. <strong>CIL006 targets oxidative stress<\/strong>, with an initial focus on a rare hearing disorder.<\/p><p>Cilcare will advance both programs through preclinical proof of concept, using its proprietary disease models and translational expertise in hearing sciences.<\/p><p>The financial terms have not been disclosed.<\/p><p><em>\u201c<\/em><em>Our strategy is to build a differentiated pipeline that reflects the biological diversity of hearing disorders and addresses significant unmet medical needs. CIL005 and CIL006 broaden the scope of our portfolio, allowing us to target distinct disease mechanisms and expand into patient populations with limited therapeutic options,\u201d <\/em>said <strong>Patricia Machado, Early Drug Development and Pipeline Director<\/strong> <strong>at Cilcare.<\/strong><\/p><p><em>\u201cThese programs strengthen and diversify our pipeline, and further validate our ability to identify and advance promising opportunities in hearing health. They also reflect our continued partnership with Sanofi, our minority shareholder\u201d<\/em>, said <strong>Celia Belline, Chief Executive Officer of Cilcare.<\/strong><\/p><p><strong><em>About CILCARE<\/em><\/strong><strong>: <\/strong>Cilcare is a biopharmaceutical company pioneering auditory science, with expertise in drugs and diagnostics designed to prevent and treat hearing disorders. Built on deep auditory neuroscience capabilities, Cilcare supports preclinical and clinical development for its own pipeline and for industrial and academic partners worldwide. Headquartered in Montpellier, France, with subsidiaries in Boston, MA and Tokyo, Cilcare operates across Europe, USA, and Asia. For more information, please visit <strong><a href=\"https:\/\/www.cilcare.com\/jp\/\">www.cilcare.com<\/a>\u00a0<\/strong><\/p><p>Download the Press Release:<\/p><ul><li><strong><a href=\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/CP_Cilcare_Sanofi_CIL005_CIL006_final.pdf\">In English<\/a><\/strong><\/li><li><strong><a href=\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/CP_Cilcare_Sanofi_CIL005_CIL006_final_FR.pdf\">In French<\/a><\/strong><\/li><\/ul><p><strong><u>Contacts<\/u><\/strong><strong>\u00a0<\/strong><\/p><p>Marie PEYTAVY \/ Marketing &amp; Communication Director <a href=\"mailto:marie.peytavy@cilcare.com\">marie.peytavy@cilcare.com<\/a> \/ +33 7 69 74 19 05<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b845b78 e-flex e-con-boxed e-con e-parent\" data-id=\"b845b78\" data-element_type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>CIL005 and CIL006 extend Cilcare\u2019s pipeline to new mechanisms of hearing loss and new patient populations Montpellier, France, November 16, 2026 \u2013 Cilcare, a biotechnology company pioneering auditory science, today announced exclusive licensing agreements with Sanofi for two therapeutic assets, CIL005 and CIL006. The programs expand Cilcare\u2019s proprietary pipeline beyond cochlear synaptopathy, the focus of its lead candidate CIL001. Two programs targeting complementary mechanisms As in any other organ, the inner ear relies on many cell types, each of which can be damaged through distinct biological mechanisms that define different disorders and patient populations. CIL005 and CIL006 expand Cilcare\u2019s pipeline into two complementary areas of hearing biology. \u00a0CIL005 targets cochlear [&hellip;]<\/p>","protected":false},"author":6,"featured_media":14658,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[114],"tags":[166],"class_list":["post-14639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","tag-cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi","entry","has-media"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi<\/title>\n<meta name=\"description\" content=\"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cilcare.com\/jp\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi\" \/>\n<meta property=\"og:description\" content=\"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cilcare.com\/jp\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/\" \/>\n<meta property=\"og:site_name\" content=\"Cilcare\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T07:00:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/miniature-news-logos.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"marie.peytavy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"marie.peytavy\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/\",\"url\":\"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/\",\"name\":\"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi\",\"isPartOf\":{\"@id\":\"https:\/\/www.cilcare.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/miniature-news-logos.png\",\"datePublished\":\"2026-11-16T07:00:58+00:00\",\"author\":{\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/345b0ccb59d96b17a6908a76cad8e256\"},\"description\":\"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#primaryimage\",\"url\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/miniature-news-logos.png\",\"contentUrl\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/miniature-news-logos.png\",\"width\":1200,\"height\":675,\"caption\":\"Cilcare-Sanofi licensing agreements\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cilcare.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cilcare.com\/#website\",\"url\":\"https:\/\/www.cilcare.com\/\",\"name\":\"Cilcare\",\"description\":\"Making hearing a priority\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cilcare.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/345b0ccb59d96b17a6908a76cad8e256\",\"name\":\"marie.peytavy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5de15f4de6ecabd3b374a0d5608780aae06de6510a1b70c8fdf69e014f99cfbc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5de15f4de6ecabd3b374a0d5608780aae06de6510a1b70c8fdf69e014f99cfbc?s=96&d=mm&r=g\",\"caption\":\"marie.peytavy\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi","description":"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cilcare.com\/jp\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/","og_locale":"ja_JP","og_type":"article","og_title":"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi","og_description":"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi","og_url":"https:\/\/www.cilcare.com\/jp\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/","og_site_name":"Cilcare","article_published_time":"2026-11-16T07:00:58+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/miniature-news-logos.png","type":"image\/png"}],"author":"marie.peytavy","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"marie.peytavy","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/","url":"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/","name":"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi","isPartOf":{"@id":"https:\/\/www.cilcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#primaryimage"},"image":{"@id":"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/miniature-news-logos.png","datePublished":"2026-11-16T07:00:58+00:00","author":{"@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/345b0ccb59d96b17a6908a76cad8e256"},"description":"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi","breadcrumb":{"@id":"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#primaryimage","url":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/miniature-news-logos.png","contentUrl":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2026\/11\/miniature-news-logos.png","width":1200,"height":675,"caption":"Cilcare-Sanofi licensing agreements"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cilcare.com\/2026\/11\/16\/cilcare-strengthens-its-therapeutic-pipeline-with-two-new-exclusive-licensing-agreements-with-sanofi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cilcare.com\/"},{"@type":"ListItem","position":2,"name":"Cilcare strengthens its therapeutic pipeline with two new exclusive licensing agreements with Sanofi"}]},{"@type":"WebSite","@id":"https:\/\/www.cilcare.com\/#website","url":"https:\/\/www.cilcare.com\/","name":"Cilcare","description":"Making hearing a priority","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cilcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/345b0ccb59d96b17a6908a76cad8e256","name":"marie.peytavy","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5de15f4de6ecabd3b374a0d5608780aae06de6510a1b70c8fdf69e014f99cfbc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5de15f4de6ecabd3b374a0d5608780aae06de6510a1b70c8fdf69e014f99cfbc?s=96&d=mm&r=g","caption":"marie.peytavy"}}]}},"_links":{"self":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/14639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/comments?post=14639"}],"version-history":[{"count":14,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/14639\/revisions"}],"predecessor-version":[{"id":14657,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/14639\/revisions\/14657"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/media\/14658"}],"wp:attachment":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/media?parent=14639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/categories?post=14639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/tags?post=14639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}